Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648633 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
A Phase 1 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02648633: Clinical Trial Phase 1 study, sponsored by University of Virginia.
NCT02648633 is a Phase 1 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02648633, a Phase 1 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and feasibility of the immunotherapeutic agent nivolumab given in combination with gamma knife therapy and valproate in patients with recurrent glioblastoma, a common and lethal type of brain cancer.
Primary Outcome
Feasibility of the radiosurgery and drug combination will be determined based on the number of subjects who complete at least 4 doses of nivolumab.
Interventions
- DRUG Nivolumab
- RADIATION Stereotactic Radiosurgery
- DRUG Valproate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-05-24 |
| Est. Completion | 2017-02-21 |
| Phase | Phase 1 |
Why NCT02648633 stopped before completion
NCT02648633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02648633 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02648633 about?
NCT02648633 is a clinical study titled "Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma". The purpose of this study is to evaluate the safety and feasibility of the immunotherapeutic agent nivolumab given in combination with gamma knife therapy and valproate in patients with recurrent glioblastoma, a common and lethal type of brain cancer.
What is the current status of trial NCT02648633?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-05-24. Estimated completion is 2017-02-21.
What interventions are being tested in trial NCT02648633?
The interventions under investigation include: Nivolumab (DRUG), Stereotactic Radiosurgery (RADIATION), Valproate (DRUG).
Who is sponsoring clinical trial NCT02648633?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02648633's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI